Adenocarcinoma Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

In conversation with... Paula Ghaneh
Paula Ghaneh (University of Liverpool) discusses the ESPAC5 randomised controlled trial of short-course neoadjuvant therapy compared with immediate surgery for patients with borderline resectable pancreatic ductal adenocarcinoma. (Source: Listen to The Lancet)
Source: Listen to The Lancet - January 24, 2023 Category: General Medicine Authors: The Lancet Source Type: podcasts

JAMA Oncology : Adjuvant Chemotherapy in Patients With Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy
Interview with Marco Del Chiaro, MD, PhD, author of Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy. Hosted by Jack West, MD. Related Content: Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - December 8, 2022 Category: General Medicine Authors: The JAMA Network Source Type: podcasts

APACT Trial in Pancreatic Adenocarcinoma
Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center shares the results from the APACT study, a phase III tr... Author: obr Added: 07/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2019 Category: Cancer & Oncology Source Type: podcasts

APACT Study in Pancreatic Adenocarcinoma Details
Vincent Chung MD, Associate Clinical Professor and Medical Oncologist at City of Hope discusses details from APACT study, a phase III trial of adjuvant nab-paclitaxel plus gemcitabine. Author: obr Added: 06/25/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 25, 2019 Category: Cancer & Oncology Source Type: podcasts

Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
 Dr. Joseph Tabernero, MD, discusses the phase 3 keynote-062 study. Background: KEYNOTE062 (NCT02494583) was a randomized, active controlled study of 1L P or P+C vs C in pts with PD-L1 combined po... Author: Annual-Meeting Added: 06/06/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 6, 2019 Category: Cancer & Oncology Source Type: podcasts

Mutation independent approaches in adenocarcinoma including maintenance
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Sanjay Popat discusses mutation-independent approaches to the treatment of adenocarcinoma, including maintenance ... Author: imedex Added: 07/25/2017 (Source: Oncology Tube)
Source: Oncology Tube - July 25, 2017 Category: Cancer & Oncology Source Type: podcasts

Abstract Overview: Randomized Phase II Trial for Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (mPDA)
William P. Harris, MD of Seattle Cancer Care Alliance discusses metastatic pancreatic cancer for the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 4008: Randomized phase II study of PEGPH20 plu... Author: ASCO2017 Added: 06/06/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 6, 2017 Category: Cancer & Oncology Source Type: podcasts

Abstract Overview: Perioperative Chemotherapy for Resectable Pancreatic Cancer
Davendra Sohal, MD of Cleveland Clinic gives an overview of his presentation, Perioperative mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma, which was di... Author: ASCO2017 Added: 06/05/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 5, 2017 Category: Cancer & Oncology Source Type: podcasts

The difficulties in treating squamous cell lung cancer
Johan Vansteenkiste, MD, PhD of University Hospitals Leuven, Belgium talks about how patients with squamous cell carcinoma of the lung do worse than those with adenocarcinoma of the lung. Squamous cel... Author: VJOncology Added: 02/14/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 14, 2017 Category: Cancer & Oncology Source Type: podcasts

FAST: a Phase III trial of an anti-CLDN18.2 antibody GEJ adenocarcinoma
Press brief by Salah-Eddin Al-Batran, MD of the Krankenhaus Nordwest-University Cancer Center, Frankfurt, Germany, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held ... Author: VJOncology Added: 06/29/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 29, 2016 Category: Cancer & Oncology Source Type: podcasts

ELCC 2016: Phase 2 trial of chemotherapy plus gefitinib as first-line treatment for lung adenocarcinoma
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses a phase 2 tria... Author: VJOncology Added: 05/10/2016 (Source: Oncology Tube)
Source: Oncology Tube - May 10, 2016 Category: Cancer & Oncology Source Type: podcasts

Histology-Specific Regimens - Adenocarcinoma
Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology. http://cancergrace.org/lung...... Author: cancergrace Added: 04/18/2016 (Source: Oncology Tube)
Source: Oncology Tube - April 18, 2016 Category: Cancer & Oncology Source Type: podcasts

Pembrolizumab more value in squamous cell carcinomas or adenocarcinomas ASCO GI 2016
Dr. Toshihiko Doi, MD of National Cancer Center Hospital East, Japan discusses pembrolizumab and more value in squamous cell carcinomas or adenocarcinomas ASCO GI 2016 Author: ASCOGI2016 Added: 01/29/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 29, 2016 Category: Cancer & Oncology Source Type: podcasts